# Cancer vaccine development gets complicated

Source: [nature.com](https://www.nature.com/articles/d41573-026-00181-8) · 2026-11-13 · Medicine
Page: https://themorning.science/story/cancer-vaccine-development-gets-complicated-924117124355698b
Kind: research · Impact: medium

## In brief

- Merck and Moderna's intismeran autogene succeeded in a landmark melanoma trial.
- The oncology community still has more questions than answers about the future of cancer vaccines.
- The article is a Nature Reviews Drug Discovery piece published online 13 November 2026.

## Why it matters

The melanoma trial result is an early landmark for individualized mRNA-style cancer vaccines, but open questions about their future affect how researchers design and evaluate future trials.

## Coverage

- [Cancer vaccine development gets complicated](https://www.nature.com/articles/d41573-026-00181-8) — nature.com, 2026-11-13

Tags: cancer vaccines, melanoma, immunotherapy, clinical trials, mrna

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science